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Abstract: For thousands of years medicine and natural products have been closely linked through the use of traditional medicines and 
natural poisons. Mushrooms have an established history of use in traditional oriental medicine, where most medicinal mushroom prepara-
tions are regarded as a tonic, that is, they have beneficial health effects without known negative side-effects and can be moderately used 
on a regular basis without harm. Mushrooms comprise a vast and yet largely untapped source of powerful new pharmaceutical products. 
In particular, and most importantly for modern medicine, they represent an unlimited source of compounds which are modulators of tu-
mour cell growth. Furthermore, they may have potential as functional foods and sources of novel molecules. We will review the com-
pounds with antitumor potential identified so far in mushrooms, including low-molecular-weight (LMW, e.g. quinones, cerebrosides, 
isoflavones, catechols, amines, triacylglycerols, sesquiterpenes, steroids, organic germanium and selenium) and high-molecular-weight
compounds (HMW, e.g. homo and heteroglucans, glycans, glycoproteins, glycopeptides, proteoglycans, proteins and RNA-protein com-
plexes).  
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1. INTRODUCTION 
 Over recent decades consumer demands in the field of food 
production have changed considerably. Consumers increasingly 
believe that foods contribute directly to their health and well-being. 
Today’s foods are not only intended to satisfy hunger and provide 
the required nutrients but also to prevent diseases and improve 
physical and mental well-being of consumers. In this context, func-
tional foods play a very significant role. The increasing demand for 
such foods can be explained by the rapid advances in science and 
technology, increasing healthcare costs, changes in food laws af-
fecting label and product claims, the steady increase in life expec-
tancy, the desire of older people for improved quality of life in their 
later years and rising interest in maintaining good health through 
diet [1]. 
 According to the Institute of Medicine’s Food and Nutrition 
Board, “Functional Foods” are foods or dietary components that 
may provide a health benefit beyond basic nutrition. We can take 
greater control of our health through the food choices we make, 
knowing that some food can provide specific health benefits [2].  
 Functional foods could not exist without nutraceutical com-
pounds, the bioactive compounds that give functional properties to 
food. A nutraceutical can be defined as a substance that may be 
considered a food or part of a food and may possibly provide medi-
cal or health benefits such as the prevention and treatment of dis-
ease. Nutraceuticals may range from isolated nutrients and dietary 
supplements to genetically engineered “designer” foods, herbal 
products and processed products such as cereals, soups and bever-
ages [3]. 
 When considering natural species as sources of compounds 
with potential medicinal properties, Baker et al. [4] suggested that 
one should take into account the: i) evidence regarding the tradi-
tional usage of the substance by indigenous populations, ii) abun-
dance of the species in nature and iii) sustainable utilisation of the 
species. These criteria were suggested for the discovery of natural 
products from the Plant Kingdom. However, fungi, a separate
Kingdom from plants, could also complete these criteria and most
importantly, the sustainability of fungi can be achieved by using 
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artificial cultivation techniques. Another extremely important crite-
rion when searching for novel bioactive compounds is the unique-
ness of the organism and its potential to produce secondary metabo-
lites [5]. In fact, in addition to the ancient utilization of plants, the 
medicinal use of mushrooms also has a very long tradition. Among 
the large resources of fungi, higher Basidiomycetes, especially 
mushrooms, represent unlimited sources of therapeutically useful 
biologically active agents [6-8]. In particular, mushrooms with 
potential useful properties against cancers of the stomach, esopha-
gus, lungs, etc. are known in China, Japan, Korea, Russia, United 
States and Canada [9]. 
 The number of mushroom species on earth is estimated to be 
140,000, suggesting that only 10% are already known. Assuming 
that the proportion of useful mushrooms among the undiscovered 
and unexamined mushrooms will be only 5% (a small logical %), 
this implies 7,000 yet undiscovered species of possible benefit to 
mankind [10]. The higher Basidiomycetes include about 10,000 
species from 550 genera and 80 families in the Basidiomycetes 
class with macroscopic fruiting bodies. Furthermore, approximately 
700 species of higher Basidiomycetes have been found to possess 
significant pharmacological activities [6,7,9]. The macrofungi have 
been divided into four groups: edible flesh, medicinal, poisonous 
and miscellaneous, where the properties are less well defined [11].  
 It is not surprising that mushrooms are a source of many bio-
logically active compounds. Mushrooms manage to grow in dark-
ness and dampness in highly competitive environments and protect 
themselves from hordes of attacking microbes by developing natu-
ral protective substances. Modern scientific studies on the above 
called “medicinal mushrooms” have expanded exponentially during 
the last two decades and scientific explanation to show how com-
pounds derived from mushrooms function in humans are increas-
ingly being established [12]. Fungal fruiting bodies, fungal myce-
lium or the culture fluid in which the mycelium has been cultivated 
may all be explored for biological activity. More recently, some 
species of edible higher Basidiomycetes have been found to mark-
edly inhibit the growth of different tumor cell lines. There are ap-
proximately two hundred species of higher Basidiomycetes that 
were found to have this activity [13]. Additionally, both cellular 
components and secondary metabolites of a large number of mush-
rooms have been shown to affect the immune system and therefore 
might be used to treat a variety of diseases [9]. Mushrooms which 
appear to enhance or potentiate resistance to disease states are being 
sought for the treatment of cancer, immunodeficiency diseases (in-
cluding AIDS) or generalized immunosuppression after drug treat-
ment [14,15]. 
 The above named “medicinal mushrooms” have an established 
history of use in traditional oriental medicine, where most medici-
nal mushroom preparations are regarded as a tonic, that is, they are 
claimed to have beneficial health effects without known negative 
side-effects and can apparently be moderately used on a regular 
basis without harm. Often, blends of various medicinal mushrooms 
are used for maximum benefit. Many traditionally used mushrooms 
from genera, Auricularia, Flammulina, Ganoderma, Grifola, Heri-
cium, Lentinus (Lentinula), Pleurotus, Trametes (Coriolus), Schizo-
phyllum, and Tremella have been demonstrated to possess signifi-
cant medicinal potential [7,16]. Pleurotus eryngii, Lyophyllum 
shimeji, Flammulina velutipes and Grifola frondosa are edible 
mushrooms that have all been found to contain medicinally active 
compounds with potential benefit to health. However, many edible 
species of potent medicinal mushrooms such as Ganoderma lu-
cidum, Trametes versicolor and Inonotus obliquus are very bitter 
and/or hard to eat and are used in the form of an extract, tea or 
powder [8,17]. From the edible mushroom species, Agaricus are the 
leader in world production, whilst from the non-edible medicinal 
species, Ganoderma (which belongs to the polypores) are the leader 
in terms of world production. Several mushroom species belonging 
to the Polyporaceae family are now being regarded as the next 
candidate producers of possible valuable medicines [6]. 
 The spectrum of detected pharmacological activities of-
Basidiomycetes is very broad; among their biological effects, the 
following have been suggested: antifungal, anti-inflammatory, anti-
tumor, antiviral, antibacterial, antiparasitic, immunomodulating and 
hepatoprotective; equally promising is their suggested role in the 
regulation of blood pressure, as well as in the cure of cardiovascular 
disorders, in hypercholesterolemia and diabetes [18]. Even among 
the known species, the proportion of well-investigated mushrooms 
is very low. This fact, together with the knowledge about the great 
potential of microscopic fungi for production of bioactive metabo-
lites [e.g. Penicillium, Aspergillus, Tolypocladium inflatum W. 
Gams, Claviceps purpurea (Fr.) Tul.], the experience in ethnomedi-
cinal use of mushrooms, the ecologic need for fungi to produce 
bioactive secondary metabolites and the improved possibilities for 
genetic, pharmacological and chemical analysis led to the assump-
tion that mushrooms have great potential for successful bio-
prospecting [19]. 
 In summary, wild mushrooms have been widely used as human 
food for centuries and have been appreciated for their texture and 
flavors as well as some suggested medicinal and tonic attributes. 
However, the awareness of mushrooms as a healthy food and as an 
important source of biologically active substances with medicinal 
potential has only recently emerged. Various activities of mush-
rooms have been studied which include antibacterial, antifungal, 
antioxidant, antiviral, antitumor, cytostatic, immunosuppressive, 
antiallergic, antiatherogenic hypoglycemic, anti-inflammatory and 
hepatoprotective activities [19]. In this review we have collected 
evidence of mushrooms and compounds extracted from mushrooms 
which have potential antitumor properties. 
2. MUSHROOMS AS MODULATORS OF THE CARCINO-
GENIC PROCESS  
 Carcinogenesis is a process which normally takes several years 
during which progressive genetic changes occur leading to malig-
nant transformation. Cancer prevention is the best intervention in 
this process before invasive disease develops. Over the last half 
century, our understanding of carcinogenesis has grown enor-
mously, owing largely to recent technology, allowing exploration of 
molecular pathways, cancer-associated genes and tissue architec-
ture. This knowledge provided the basis for most cancer-preventive 
intervention strategies and particularly for one of the strategies, 
chemoprevention – the use of drugs, biologicals and nutrients to 
prevent the development of cancer (i.e. to inhibit, delay or reverse 
carcinogenesis) [20]. Carcinogenesis has traditionally been under-
stood as having three stages: initiation, promotion, and progression. 
Although more recently carcinogenesis has not been described in 
those terms, but rather as a malignant transformation as a whole, we 
hereby refer to the literature in which such divisions of the stages of 
carcinogenesis were made. It has been described that the modula-
tion of the human immune system, attributed to mushrooms, par-
ticularly to various mushroom polysaccharides, was likely to affect 
primarily the promotion and progression stages, according to the 
referred model of carcinogenesis. Nonetheless, other substances 
contained in mushrooms were described as possibly being able to 
interfere with the referred tumor initiation process, through a vari-
ety of mechanisms such as enhancing the antioxidant capacity of 
cells or upregulating phase I and II enzymes involved in the meta-
bolic transformation and detoxification of mutagenic compounds. 
Additionally, other mushroom constituents have been described as 
being able to inhibit what was considered to be the promotion or 
progression stages of carcinogenesis, by exerting direct cytotoxicity 
against tumor cells, interfering with tumor angiogenesis, or upregu-
lating other nonimmune tumor-suppressive mechanisms [21]. 
 Many species of Fungi from the division Basidiomycetes (mus-
hrooms) have been found to contain medicinally active compounds, 
which has been of great recent interest [8,12,21-26]. There are ad-
vantages of using mushrooms as sources of bioactive compounds, 
rather than plants. For example, the fruiting body can be produced 
in much less time and the mycelium may also be rapidly produced 
(in a liquid culture that can be manipulated to produce optimal 
quantities of active products, or from mycelial biomass and super-
natant of submerged cultures using bioreactors) [27-31]. 
3. COMPOUNDS FROM MUSHROOMS WITH ANTITU-
MOR POTENTIAL 
 Mushrooms comprise a vast and yet largely untapped source of 
powerful new pharmaceutical products. In particular, and most 
importantly for modern medicine, they represent an unlimited 
source of compounds with potential antitumor and immunostimulat-
ing properties, including low-molecular-weight (LMW, e.g. quino-
nes, cerebrosides, isoflavones, catechols, amines, triacylglycerols, 
sesquiterpenes, steroids, organic germanium and selenium) and 
high-molecular-weight compounds (HMW, e.g. homo and hetero-
polysaccharides, glycoproteins, glycopeptides, proteins, RNA-
protein complexes) Fig. (1). We hereby review each of these com-
pounds and their described potential antitumor properties. 
3.1. Low Molecular Weight Compounds with Antitumor  
Potential 
 Mushrooms contain a variety of complex compounds derived 
from secondary metabolism such as phenolic compounds, 
polyketides, triterpenoids and steroids which are specific to each 
mushroom and have specific effects in humans [8,12,21,25,32]. 
Many such compounds have been used in the treatment of many 
health problems, including cancer [33].  
 The secondary metabolites with LMW present in mushrooms 
and which have revealed antitumor properties include quinones, 
cerebrosides, isoflavones, catechols, amines, triacylglycerols, ses-
quiterpenes, steroids, organic germanium and selenium Table 1;
Fig. (2).
 Two epoxy compounds derivatives of quinones (1 and 2) are 
involved in modulating the activity of NF-kB, which is implicated 
in tumor growth [12]. Clavilactones (3a,b- quinones and 3c-hydro-
quinone) are fungal metabolites endowed with an unsual structure, 
based on a 10-membered macrolide fused to a benzoquinoid ring 
and a 2,3-epoxy--lactone [34,35]. They were isolated from the 
culture medium of the non-toxigenic basidiomycetae Clitocybe 
clavipes. These compounds were identified as inhibitors of protein 
tyrosine kinases [12].  
Fig. (1). Low-molecular-weight (LMW) and high-molecular-weight (HMW) compounds with antitumor potential found in mushrooms.
 A potent sulfhydryl reagent appears in the gill tissues of the 
mushroom Agaricus bisporus in the period prior to sporulation. 
This agent, termed the 490 quinone (4) because of its maximum 
wavelength at 490 nm, has been postulated to play a role in the 
induction of cryptobiosis in the spore though inhibition of energy 
and DNA synthesis [36]. This compound markedly inhibited L1210 
murine leukemia DNA polymerase . The inhibition of DNA syn-
thesis by the 490 quinone may contribute significantly to the cyto-
toxicity of this compound [12].  
 Two compounds from Ganoderma lucidum that inhibit eukary-
otic DNA polymerase were identified as cerebrosides: (4E,8E)-N-
D-2-hydroxypalmitoyl-1-O--D-glucopyranosyl-9-methyl-4,8-
sphingadienine (6a) and (4E,8E)-N-D-2-hydroxystearoyl-1-O--D-
glucopyranosyl-9-methyl-4,8-sphingadienine (6b). These cere-
brosides selectively inhibited the activities of replicative DNA po-
lymerases, especially the -type, from phylogenetically broad eu-
karyotic species, whereas they had little effect on the activities of 
DNA polymerase , prokaryotic DNA polymerases, terminal de-
oxynucleotidyl transferase, HIV reverse transcriptase, RNA polym-
erase, deoxyribonuclease I and ATPase. The inhibition of another 
replicative polymerase, the -type, was moderate [12,33]. 
 The hydroquinone (E)-2-(4-hydroxy-3-methyl-2-butenyl)-hyd-
roquinone (5) and polyporenic acid C (24) were isolated as matrix 
metallo-proteinase (MMPs) inhibitors, from the mushroom Pip-
toropus betulinus. This mushroom has been traditionally used in 
Czech Republic as a functional food for the treatment of rectal can-
cer [19]. Compound 24 was also isolated from Daedalea dickinsii.
MMPs mediate physiological extracellular matrix remodelling and 
have been implicated in several pathological processes including 
tumor growth and metastasis [37]. 
 In human hepatocellular carcinoma cells (HepG2), the isofla-
vone genistein (7) was found to modulate Cdc2 kinase activity and 
lead to G2/M arrest [38]. Furthermore, this compound suppressed 
the proliferation of p53-null human prostate carcinoma cells. The 
inhibitory effects of genistein on cell growth and proliferation were 
associated with a G2/M arrest in cell cycle progression, concomi-
tant with a marked inhibition of cyclin B1 and an induction of Cdk 
inhibitor p21WAF1/CIP1 in a p53-independent manner [39]. 
 The naturally occurring 6-(3,4-dihydroxystyryl)-4-hydroxy-2-
pyrone (hispidin) (8) was isolated from the culture broth of 
Phellinus linteus, Gymnopilus marginatus, G. patriae, G. parvis-
porus and Inonotus hispidus. Hispidin is a potent inhibitor of 
PKC, a protein kinase which plays an important role in angiogene-
sis [12]. Hispidin synthesised by Gonindard et al. [40] was shown 
to be cytotoxic toward human keratinocytes (SLC-1 tumour cell 
line) and human pancreatic duct cells (Capan-1 tumour cell line). 
More importantly, the addition of hispidin in three successive doses 
led to a 100-fold increase in activity with an enhanced activity on 
cancer cells compared to normal cells. 
Table 1. Low-Molecular-Weight Compounds with Antitumor Potential 
Class Antitumor Agents Mushroom Species Molecular Targets References 
Panepoxydone (1) 
Panus conchatus, P. rudis, 
Lentinus crinitus NF-KB inhibitor [12] 
Cycloepoxydon (2) Xylaria strain 45-93 NF-KB inhibitor [12] 
Clavilactones CB (3a), CD (3b) and CA (3c) Clitocybe clavipes Tyrosine kinase inhibitors [12,34,35]
490 Quinone (-L-glutaminyl-4-hydroxy-2,5-benzoquinone) (4) Agaricus bisporus 
DNA polymerase  inhibi-
tor [12,36]
Quinones 
(E)-2-(4-hydroxy-3-methyl-2-butenyl)-hydroquinone (5) Piptoporus betulinus MMPs inhibitor [12,19]
(4E,8E)-N-D-2’-hydroxypalmitoyl-1-O--D-glucopyranosyl-9-methyl-4,8-
sphingadienine (6a) 
Cerebrosides 
(4E,8E)-N-D-2’-hydroxystearoyl-1-O--D-glucopyranosyl-9-methyl-4,8-
sphingadienine (6b) 
Ganoderma lucidum 
DNA polymerase  inhibi-
tors [12,33]
Isoflavones Genistein (7) Flammulina velupites Cdc2 kinase modulator [12,38,39]
6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyrone (Hispidin) (8) 
P. linteus, Gymnopilus mar-
ginatus, G. patriae, G. 
parvisporus, Ionotus hispidus 
PKC inhibitor [12,40]
Catechols 
Gerronemins A-F (9a-f) Gerronema  COX-2 inhibitors [12,43]
2-aminophenoxazin-3-one (10) Lepiota americana Aromatase inhibitor [12,41]
Amines 
Putrescine-1,4-dicinnamide (11) Pholiota spumosa 
Not known (inducer of 
apoptosis and necrosis) [13,47]
Triacylglycerols 1-Oleoyl-2-linoleoyl-3-palmitoylglycerol (12) Grifola frondosa Cyclooxygenase inhibitor [12,44]
Sesquiterpenes Iludin S and M (13a,b) and derivatives 
Omphalotus illudens, Lamp-
teromyces japonicus 
One drivative is DNA-
alkylating agents [12,13]
5,8-Epidioxy-24(R)-methylcholesta-6,22-dien-3-ol (14a) 
Lepiota americana,  
Cordyceps sinensis  Sulfatase inhibitor [12,41]
5,8-Epidioxy-24(R)-methylcholesta-6,22-dien-3-D-glucopyranoside (14b) 
5,6-Epoxy-24(R)-methylcholesta-7,22-dien-3-ol (14c) Cordyceps sinensis Not known [42] 
Ergosterol (15) 
Grifola frondosa, Agaricus 
blazei Cyclooxygenase inhibitor [12,44,46]
Ergosta-4,6,8(14),22-tetraen-3-one (16)
Grifola frondosa, Ganoderma 
applanatum, G. neo-
japonicum 
Cyclooxygenase inhibitor [12,44,45]
Lucidenic acid O (17a) 
Lucidenic lactone (17b) 
Cerevisterol (18) 
Lucidumol A (19) and B (20a) 
Ganoderiol F (20b) 
Ganodermanondiol (20c) 
Ganodermanontriol (20d) 
Ganoderic acids A (21a), F (21b), H (21c), W (22), X (23a), Y (23b), T (23c) 
Ganoderma lucidum 
DNA polymerase ,  and 
RT inhibitors (17a and 17b) 
DNA polymerase  inhibi-
tor (18) 
NF-KB and AP-1 inhibitors 
(21a and 21c) 
DNA topoisomerase inhibi-
tor (23a)  
[12,33,48-
52]
Polyporenic acid C (24) 
Piptoporus betulinus, 
Daedalea dickinsii MMPs inhibitor [12,19]
Dehydroebriconic acid (25) Poria cocos 
DNA topoisomerase II 
inhibitor [12]
Steroids 
Fomitellic acids A and B (26a,b) Fomitella fraxinea 
DNA polymerase  and 
inhibitors [12] 
Organic germa-
nium Bis--carboxyethylgermanium sesquioxide: O3(GeCH2CH2COOH)2 Ganoderma lucidum Not known [48,53]
Trace elements Selenium 
Agaricus bisporus, Boletus 
edulis, Flammulina velutipes, 
Pleurotus ostreatus 
DNA cytosine methyltrans-
ferase inhibitor [12] 
 Sulfation and desulfation are important reactions in the metabo-
lism of many steroid hormones. Aromatase inhibitors are used 
widely as second-line therapy in breast cancer and there is now 
evidence of a chemopreventive role for these agents [12]. Aro-
matase and sulfatase inhibitors were isolated from an edible mush-
room, Lepiota americana. 2-Aminophenoxazin-3-one (10) inhibited 
aromatase, and 5,8-epidioxy-24(R)-methylcholesta-6,22-dien-3-ol 
(14a) inhibited sulfatase [41]. 
 Compound 14a and two more steroids 5,8-epidioxy-24(R)-
methylcholesta-6,22-dien-3-D-glucopyranoside (14b) and 5,6-
epoxy-24(R)-methylcholesta-7,22-dien-3-ol (14c) isolated from 
Cordyceps sinensis inhibited the proliferation of K562, Jurkat, 
WM-1341, HL-60 and RPMI-8226 tumor cell lines [42]. 
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Fig. (2). Chemical structure of the low-molecular-weight (LMW) compounds with antitumor potential found in mushrooms. 
 It is now well established that the inducible isoform of cyclo-
oxygenase, COX-2, is commonly over-expressed in many solid 
tumors. Epidemiological studies and clinical trials employing selec-
tive and nonselective COX-2 inhibitors indicate that COX-2 is 
mechanistically involved in colorectal carcinogenesis, gastric carci-
noma, breast cancer, and prostate cancer [12]. The gerronemins A-F 
(9) blocked the inducible expression of a hCOX-2 and iNOS pro-
moter driven reporter gene. These compounds were isolated as the 
cytotoxic components of an extract from a Gerronema species, 
found in the process of screening for new cytotoxic metabolites 
from basidiomycetes. Their structures were elucidated by spectro-
scopic techniques, and are composed of a C12-C16 alkane or alkene 
substituted at both ends by 2,3-dihydroxyphenyl groups [43]. 
 Other inhibitors of COX-1 and COX-2 enzymes are the com-
pounds 15 ergosterol, 16 ergosta-4,6,8(14),22-tetraen-3-one and 12
1-oleoyl-2-linoleoyl-3-palmitoylglicerol and were isolated from 
Grifola frondosa [12,44]. Compound 16 was also isolated from 
Ganoderma applanatum and G. neo-japonicum [45]. Compound 15
(ergosterol) was additionally isolated from the lipid fraction of 
Agaricus brasiliensis and retarded tumor growth in Sarcoma 180-
bearing mice. In studies in vivo ergosterol inhibited neovascularisa-
tion, being a possible inhibitor of angiogenesis [12,46]. 
HO
15
O
16
HO
R2
OH
R1
O
OH
17a R1 = CH2OH, R
2 =
CH2
COOH
17b R1 = CH3, R
2 =
O
CH2OH
O
HO
R2
OH
R1
O
OH
17a R1 = CH2OH, R
2 =
CH2
COOH
17b R1 = CH3, R
2 =
O
CH2OH
O
HO
OH
OH
18
O
OH
O 19
R4
R5
R1
R2
R3
20a R1=R2=OH,H, R3=OH, R4=R5=CH3
20b R1=O, R2=H2, R3= 24(25), R4=R5=CH2OH
20c R1=O, R2=OH,H, R3=OH, R4=R5=CH3
20d R1=O, R2=OH,H, R3=OH, R4=CH2OH, R5=CH3
R2
R4
R1
O O
COOH
R3
21a R1=O, R2=R4=OH, R3=H 
21b R1=OH, R2=O, R3=OAc, R4=O
21c R1=R2= R4=O, R3=OAc
COOH
AcO OH
OAc
22
R1
R2
H
COOH
23a R1=OH, R2=OAc , R3=H
23b R1=OH, R2=R3=H
23c R1=R2=R3=OAc
R3
R
OH
HOOC
24 R=O
25 R=OAc
HO
R
O
OH
H
HO2C H
26a R=OH
26b R=H
 Pholiota spumosa produces a polyamine (putrescine-1,4-dicin-
namide) (11) that inhibits the growth of human prostate cancer cell 
lines, inducing apoptotic cell death. This is mediated, at least partly, 
by the activation of caspase cascades. At higher doses the mode of 
cell death was described as necrosis [13,47].  
 Omphalotus illudens and Lampteromyces japonicus produce 
compounds with potential antitumor properties, as sesquiterpenes 
illudin S (13a) and illudin M (13b). Because of its high toxicity, 
illudin S was not studied further and hemisynthetic derivatives were 
produced as irofulven, a compound that demonstrates possible anti-
cancer properties against solid tumors, by working as a DNA-
alkylating agent. In addition, its cytotoxicity seems to be more spe-
cifically addressed against malignant cells, having shown less selec-
tivity for normal cells [13]. Irofulven has demonstrated antitumor 
potential against various human cancer cell lines such as pancreatic 
carcinoma, colorectal carcinoma, ovarian carcinoma, non-small-cell 
lung cancer and malignant glioma, amongst others [12]. 
 Ganoderma lucidum is a mushroom with many interesting 
compounds [13,33]. These include polysaccharides of -glucan 
type and proteins such as LZ-8, as it will be discussed in the next 
section, but also steroids 17-23. The described antitumor potential 
of such compounds is similar to that described for -D-glucans: 
activators of the NF-kB pathway and modulators of Ras/Erk, c-
myc, CREB protein and mitogen-activated protein kinases [12,48]. 
Lucidenic acid O (17a) and lucidenic lactone (17b) prevented not 
only the activities of calf DNA polymerase  and rat DNA polym-
erase , but also those of human immunodeficiency virus type 1 
reverse transcriptase. Cerevisterol (18), which was reported to be a 
cytotoxic steroid, inhibited only the activity of DNA polymerase 
[49].  
 Ganoderic acids W (22), X (23a) and Y (23b) and lanostane-
type triterpenes isolated from spores of Ganoderma lucidum, the 
ganoderic alcohols lucidumol A (19) ((24S)-24, 25-dihydro-
xylanost-8-ene-3, 7-dione) and lucidumol B (20a) (,(24S)-lanosta-
7, 9(11)-diene-3, 24, 25-triol), ganodermanondiol (20c), gano-
deriol F (20b) and ganodermanontriol (20d) have been shown to 
exert a cytotoxic effect in some tumor cell lines [48]. Ganoderic 
acid X (23a) and ganoderic acid T (23c) induced apoptosis in hu-
man hepatoma and lung cancer cells, respectively, suggesting that 
the basic lanostane structure is necessary for the biological activity 
of purified triterpenes [50]. Treatment of human hepatoma HuH-7 
cells with ganodermic acid X (23a) caused immediate inhibition of 
DNA synthesis as well as activation of ERK and JNK nitrogen-
activated protein kinases and cell apoptosis. The apoptotic molecu-
lar events were elucidated and included degradation of chromoso-
mal DNA, a decrease in the level of Bc1-xL, disruption of mito-
chondrial membrane, release of cytocrome c into the cytosol and 
activation of caspase-3. The ability of compound 23a to inhibit 
topoisomerases and to sensitize cancer cells to apoptosis makes it 
an interesting compound in the context of this review [51]. Animal 
experiments in vivo showed that compound 23c suppressed the 
growth of human solid tumors xenographed in athymic mice. It was 
also shown to markedly inhibit the proliferation of a highly metas-
tatic lung cancer cell line (95-D), by apoptosis induction (with re-
duction of mitochondria membrane potential and release of cyto-
chrome c) and cell cycle arrest at G1 phase [52]. 
 Ganoderic acid A (21a) and H (21c) suppressed the growth of 
MDA-MB-231 cells (highly invasive human breast cancer cells), 
confirmed by assays of cell proliferation and colony formation, 
together with assays of invasive behaviour (adhesion, migration and 
invasion). The compounds mediate their biological effects through 
the inhibition of the transcription factors AP-1 and NF-kappaB, 
resulting in the down-regulation of expression of Cdk4 and the 
suppression of secretion of urokinase-type plasminogen activator 
(uPA), respectively. Furthermore, the activity of ganoderic acids is 
linked to the hydroxylation in the position 7 and 15 (compound 
23a) and 3 (compound 23c) in their triterpene lanostane structure.  
 Dehydroebriconic acid (25) was found in sclerotia of Poria 
cocos. This compound potently inhibited DNA topo II activity, 
while moderately inhibited the activities of DNA polymerases , ,
, , , , , , and  from mammals, to similar extents. Fomitellic 
acids A and B (26) from the basidiomycete Fomitella fraxinea,
have selectively inhibited the activities of mammalian DNA polym-
erases  and  [12]. 
 The germanium content of Ganoderma extract is interesting 
because Ganoderma extract is claimed, like ginseng, to contain a 
comparatively high content of germanium (Ge), and this metal has 
been associated with immunomodulatory, antioxidant and antitumor 
effects [48,53]. 
 The recognition that selenium has anticancer properties, with 
the ability of mushrooms to accumulate this element, has created a 
market niche for selenium-enriched mushrooms (e.g., Agaricus 
bisporus, Flammulina velutipes, Pleurotus ostreatus). Several 
mechanisms (including DNA cytosine methyltransferase inhibition, 
antioxidant protection, enhanced immune surveillance, and inhibi-
tion of angiogenesis) have been proposed to account for the anti-
cancer potential of selenium. However, the selective induction of 
apoptosis in tumor cells may be of special significance [12].  
3.2. High Molecular Weight Compounds with Antitumor Poten-
tial 
 Many, if not all, Basidiomycete mushrooms contain biologi-
cally active compounds in fruit bodies, cultured mycelium, or cul-
ture broth [8]. Tables 2 and 3 list the type and source of some 
mushrooms’ high-molecular weight compounds with demonstrated 
antitumor potential. Among these, some polysaccharides and poly-
saccharide conjugates have been approved in some countries for the 
clinical treatment of cancer patients. They are “Lentinan” from the 
fruiting bodies of Shiitake (Lentinus edodes), “Schizophyllan” 
(Sonifilan, SPG) from the culture fluid of Suehirotake (Schizophyl-
lum commune), and “Krestin” (PSK), from the cultured mycelium 
of Kawaratake (Trametes versicolor). Lentinan and schizophyllan 
are pure -glucans, whereas PSK is a protein bound polysaccharide. 
The biological activity of these three products is related to their 
immunomodulating properties, which enhance the person’s own 
defence against various forms of infectious disease. These im-
munopotentiators, or immunoinitiators, are also referred to as “bio-
logical response modifiers” [12,54-56]. In fact, available evidence 
indicated that the antitumor properties of -glucans were attribut-
able to enhancement of the numbers and/or functions of macro-
phages, natural killer (NK) cells, and subsets of T cells, that is, the 
modulation of both innate and adaptive immunity [21]. Calvacin is 
a potent antitumor mucoprotein isolated in the 1960s from the giant 
puffball (Calvatia gigantean) fruiting body which causes a pro-
longed intoxication characterized by anorexia and extreme weight 
loss [57,58]. 
 The natural polysaccharides isolated from mushrooms, de-
scribed as having antitumor potential, include different types of 
glicosidic linkages (Table 2), while some are bound to protein or 
peptide residues such as polysaccharide-protein or -peptide com-
plexes (Table 3) [13,21,25,56,59]. Data on mushroom polysaccha-
rides, with most belonging to the group of -glucans, has been col-
lected from more than 650 species representing 182 genera of 
higher Basidiomycetes [8]. Potential antitumor activity has been 
described by a wide range of glycans, extending from ho-
mopolymers to highly complex heteropolymers (Table 2). Polysac-
charides with antitumor potential from various mushrooms are 
characterized by their molecular weight, degree of branching, and 
higher (tertiary) structure. Homoglucans are linear or branched 
molecules having a backbone composed of - or -linked glucose 
units (such as (13), (16)--glucans and (13)--glucans), and 
some contain side chains that are attached at different positions. 
Among them, -glucans are the most important polysaccharides 
with antitumor potential. These are glucose polymers that can exist
Table 2. High-Molecular-Weight Compounds with Antitumor Potential: Polysaccharides  
Class Antitumor Agents Mushroom Species Details References 
Linear (13)--D-glucan Auricularia auricula 
Lyophyllum decastes 
Immunomodulator; pre-clinical animal models [56]
(13)--D-glucan with (16)--D branches: 
Lentinan 
Schizophyllan, SPG 
Grifolan, GRN  
Scleroglucan, SSG 
Alkali-soluble glucan 
Pleuran 
SCG 
H-3-B 
PG101 
GLP 
Lentinus edodes 
Schizophyllum commune 
Grifola frondosa
Sclerotinia sclerotiorum 
Pleurotus tuber-regium 
Pleurotus ostreatus 
Sparassis crispa 
Cryptoporus volvatus 
Lentinus lepideus 
Ganoderma lucidum 
Immuno-enhancing activity; clinical trials (gastric, 
colorectal, prostate and breast cancers) 
Immuno-enhancing activity; clinical trials (gastric, 
cervical, head and neck cancers) 
Immuno-enhancing activity; clinical trials (gastro-
intestinal, lung, liver and breast cancers) 
Immunomodulator; clinical trials 
Immunomodulator; in vitro cell lines 
Immunomodulator; pre-clinical animal models 
Immunomodulator; pre-clinical animal models 
Immunomodulator; pre-clinical animal models 
Immunomodulator; pre-clinical animal models 
Immunomodulator; pre-clinical animal models 
[8,12,13,19,48,56,60-63] 
[8,12,19,21,48,56] 
[12,13,19,56] 
[48] 
[19] 
[64] 
[19,48] 
[19] 
[48] 
[48] 
(13)- -D-glucan with (12) or (16) branches Pachyman from Poria 
cocos  
Immunomodulator; pre-clinical animal models [56]
Linear (16)- -D-glucan Armillariella tabescens  
Lyophyllum decastes 
Immunomodulator; pre-clinical animal models [8,56]
(16)--D-glucan with (13)--D branches: 
D-fraction Agaricus blazei 
Grifola frondosa 
Immunomodulator; clinical trials (breast, prostate, 
lung, liver, and gastric cancers) 
[12,48,65] 
(16)--D-glucan with (14)-  branches Agaricus blazei Immunomodulator; pre-clinical animal models [56] 
(13)-- glucan Amanita muscaria 
 Agrocybe aegerita 
 Agaricus blazei 
 Armillariella tabescens 
Immunomodulator; pre-clinical animal models [8,56] 
(13)-–glucan with (16)- branches Agaricus blazei Immunomodulator; pre-clinical animal models [56] 
Homoglu-
cans 
(16)-–glucan with (14)- branches Agaricus blazei Immunomodulator; pre-clinical animal models [8] 
Arabinoglucan Ganoderma tsugae Immunomodulator; pre-clinical animal models [8,48,56] 
Galactomannoglucan Flammulina velutipes, 
Hohenbuehelia serotina, 
Leucopaxillus giganteus 
Immunomodulator; pre-clinical animal models [8,48,56]
Galactoxyloglucan Hericium erinaceus Immunomodulator; in vitro cell lines [8,48,56]
Mannogalactoglucan Agaricus blazei  
Ganoderma lucidum 
Pleurotus pulmonariu 
Pleurotus cornucopiae  
Immunomodulator; in vitro cell lines [8,48] 
Mannoxyloglucan Grifola frondosa Immunomodulator; pre-clinical animal models [8,48,56]
Riboglucan Agaricus blazei 
Flammulina velutipes 
Immunomodulator; in vitro cell lines [8,48,56] 
Xyloglucan Agaricus blazei 
Grifola frondosa  
Polyporus confluens 
Pleurotus pulmonarius 
Immunomodulator; pre-clinical animal models [8,48,56,66] 
Xylogalactoglucan Inonotus obluquus Immunomodulator; in vitro cell lines [8,48,56]
Heteroglu-
cans 
(13)--glucuronoglucan Ganoderma lucidum Immunomodulator; in vitro cell lines [48,56] 
Arabinogalactan Pleurotus citrinopileatus Immunomodulator; pre-clinical animal models [8,56]
Fucogalactan Sarcodon aspratus Immunomodulator; pre-clinical animal models [8,56] 
Fucomannogalactan Dictyophora indusiata 
 Grifola frondosa 
Immunomodulator; pre-clinical animal models [8,56] 
Glucogalactan Ganoderma tsugae Immunomodulator; pre-clinical animal models [8,48,56] 
Mannogalactan Pleurotus pulmonarius Immunomodulator; in vitro cell lines [8,48,56] 
Mannofucogalactan Fomitella fraxinea Immunomodulator; in vitro cell lines [8] 
Xylan Hericium erinaceus Immunomodulator; pre-clinical animal models [8,48,56] 
Glycans 
Glucoxylan Hericium erinaceum 
 Pleurotus pulmonarius 
Immunomodulator; pre-clinical animal models [8,48,56] 
(Table 2) contd…. 
Class Antitumor Agents Mushroom Species Details References 
Mannoglucoxylan Hericium erinaceus Immunomodulator; pre-clinical animal models [8,48,56] 
Mannogalactofucan Grifola frondosa Immunomodulator; pre-clinical animal models [8,48,56] 
Mannan Dictyophora indusiata Immunomodulator; pre-clinical animal models [8,56] 
Glucomannan Agaricus blazei Immunomodulator; pre-clinical animal models [8,48,56] 
Galactoglucomannan Lentinus edodes Immunomodulator; pre-clinical animal models [48,56] 
Galactomannan Morchella esculenta Immunomodulator; pre-clinical animal models [56] 
Tremellastin (Glucuronoxylomannans) Tremella fuciformis Immunomodulator; pre-clinical animal models [19] 
Table 3. High-Molecular-Weight Compounds with Antitumor Potential: Glycoproteins and Proteins 
Class Antitumor Agents Mushroom Species Details References 
ATOM Agaricus blazei Immunomodulator; pre-clinical animal models [48] 
AB-FP Agaricus blazei Immunomodulator; clinical trials [8,66]
PSPC Tricholoma lobayense Immunomodulator; pre-clinical animal models [48,67]
Galactoxyloglucan-protein complex Hericinum erinaceus Immunomodulator; in vitro cell lines [19] 
Glucoxylan-protein complex Hericium caput-medusae Immunomodulator; in vitro cell lines [19]
Glycoproteins (Polysac-
charide-protein com-
plexes)
Ganoderans Ganoderma lucidum Immunomodulator; in vitro cell lines [19]
PSP Trametes versicolor Immuno-enhancing activity; clinical trials  [12,13,19,31,48,56,68] 
PSK or krestin  Trametes versicolor Immuno-enhancing activity; clinical trials 
(head, neck, upper gastro-intestinal, colorectal, 
lung , and breast cancers)
[8,12,13,19,31,48,68]
KS-2 Lentinus edodes Immunomodulator; in vitro cell lines [19,60]
Glycopeptides (Polysac-
charide-peptide com-
plexes)
Glycopeptide complexes Ganoderma lucidum Immunomodulator; pre-clinical animal models [33,48]
GLIS Ganoderma lucidum Immunomodulator; pre-clinical animal models [48]
Proteoglycans 
PL Phellinus linteus Immunomodulator; pre-clinical animal models [48,69]
Mixture of polysaccha-
rides and lignin 
LEM Lentinus edodes Immunomodulator; pre-clinical animal models [19,60]
Flammulin Flammulina velutipes Immunomodulator; in vitro cell lines [19,70] 
Protein LZ8 Ganoderma lucidum Immunomodulator; pre-clinical animal models [19,48,71]
Clitocypin Clitocybe nebularis 
Cysteine proteinase inhibitor; in vitro enzy-
matic inhibition assays 
[72,73]
Proteins 
Lectins Agaricus bisporus, Boletus sa-
tanas, Grifola frondosa, 
Tricholoma mongolicum, Vol-
variella volvacea 
Immunomodulator and antiproliferative; in 
vitro cell lines 
[71] 
RNA-protein complex FA-2-b-Md Agaricus blazei Immunomodulator; in vitro cell lines [19] 
as a non-branched (13)--linked backbone or as a (13)--
linked backbone with (16)--branches, occurring as a primary 
component in the cell walls of higher fungi in great amounts [48]. It 
was described that -(13) linkages in the main chain of the glu-
can and additional -(16) branch points are needed for antitumor 
properties. The -glucans containing mainly (16) linkages have 
less activity. Besides the degree of branching, molecular weight, 
number of substituents, as well as ultrastructure, including the pres-
ence of single and triple helices, significantly affect the biological 
activities of -glucans. Higher antitumor potential seems to be cor-
related with higher molecular weight [8], lower level of branching 
and greater water solubility of -glucans. However, the high 
branched MD-fraction from G. frondosa has been shown to have 
high antitumor potential [19]. 
 Lentinan is a high molecular weight (about one million) ho-
mopolysaccharide in a triple helix structure, with linear chains con-
sisting of (1-3)--Dglucopyranosyl (Glcp) residues with two -(1-
6)-linked Glcp branchings for every five -(1-3)-Glcp residues [60]. 
This homoglucan from L. edodes has been studied in pre-clinical 
animal models and human clinical practice, and has been described 
as simultaneously demonstrating antitumor intrinsic activity and 
prophylactic ability. This compound is currently approved for the 
treatment of gastric cancer in Japan. Lentinan administered directly 
into tumors decreased the ratio of suppressor–inducer T cells and 
suppressor T cells tended to increase the ratio of cytotoxic T cells 
(CTLs) and IL-2 production of lymph node lymphocyte [61]. It has 
been shown to augment the activities of NK cells, lymphokine-
activated killer cells and CTLs. It can also activate macrophage 
differentiation and increases response in delayed-type hypersensi-
tivity against tumor antigen [48]. The single inconvenience comes 
from poor oral absorption, requiring administration by injection. 
Nonetheless, this molecule is of interest as adjunct therapy in can-
cer to induce cytostatic effects [13]. In clinical studies for antican-
cer properties, lentinan has been described as prolonging the overall 
survival of cancer patients, especially those with gastric and colo-
rectal carcinomas, metastatic prostate and breast cancer [62,63].  
 SPG from Schizophyllum commune showed antitumor activity 
against both the solid and ascite forms of Sarcoma 180, as well as 
against the solid form only of sarcoma 37, Erlich sarcoma, Yoshida 
sarcoma and Lewis lung carcinoma [8]. It has also increased cellu-
lar immunity by restoring suppressed killer-cell activity to normal 
levels in mice with tumors [21]. Human clinical studies claimed the 
benefit of treating with schizophyllan patients presenting recurrent 
and inoperable gastric cancer, stage 2 cervical cancer, and advanced 
cervical carcinoma [8]. SPG has also been shown to increase over-
all survival of patients with head and neck cancers [48]. Addition-
ally, it is also used as assistant immunotherapy in the treatment of 
gastric cancer [12].  
 Grifolan from Grifola frondosa showed antitumor potential in 
gastrointestinal, lung, liver and breast cancers [13]. This compound 
is a macrophage activator which augments cytokine production 
without dependence on endotoxins. Additionally, it enhances the 
mRNA level of IL-6, IL-1 and TNF (tumor necrosis factor)- of 
macrophages.  
 SSG, a homoglucan from Sclerotinia sclerotiorum, induces the 
development of TH1 cells via the IL-12 pathway. SCG from 
Sparassis crispa enhances the hematopoietic response [48].  
 Pleuran (-1,3-D-glucan) isolated from the oyster mushroom 
Pleurotus ostreatus has been proven to decrease the development of 
precancerous aberrant crypt foci lesions in the colon, when studied 
in the male Wistar rat [64].  
 PG101 from Lentinus lepideus can recover the radiation-
damaged bone marrow system very efficiently, increasing the levels 
of IL-1, IL-6, granulocyte macrophage-colony stimulating factor 
(GM-CSF) and reducing the level of TNF- [48]. 
 The maitake D-fraction is a relatively new compound, and there 
are a number of clinical trials in breast, prostate, lung, liver, and 
gastric cancers underway in the United States and Japan. Most of 
these are at an early clinical stage (phase I/II) [65]. 
 Heteroglucan side chains contain arabinose, galactose, man-
nose, ribose, xylose or glucuronic acid, and may have different 
combinations [8]. For example, a xyloglucan (Xyl:Glc, molar ratio 
= 2:10) containing 9% protein obtained by fractionation and purifi-
cation of Agaricus blazei extract showed significant activity against 
Sarcoma 180 in mice [66]. Another large group of bioactive poly-
saccharides is called glycans, which contain units other than glu-
cose in their backbone. They are classified as galactans, fucans, 
xylans, and mannans by the individual sugar components in the 
backbone [48]. Unlike -(13)-glucans, -(13)-glucurono-
xylomannans, which are characteristic of jelly mushrooms, are not 
strongly dependent on molecular weight [8]. Galactomannan from 
Morchella esculenta enhances macrophage activation, increasing 
nuclear factor kappa B (NF-kB)-directed luciferase expression in 
THP-1 human monocytic cells. Fucogalactan, from Sarcodon 
aspratus, increase the release of TNF- and NO in macrophages of 
mice in vitro [48]. -(12)-; -(13)-Glucomannan is a polysac-
charide active against Sarcoma 180, separated from the liquid cul-
tured mycelium of Agaricus blazei [8].  
 In some mushroom species, polysaccharides are covalently 
bound to proteins or peptides as polysaccharide-protein or -peptide 
complexes which also showed antitumor potential (Table 3). Gly-
coproteins are polysaccharide-protein complexes and such com-
pounds in mushrooms include -glucan-protein, -glucan-protein 
and heteroglycan-protein complexes. An example is a polysaccha-
ride-protein complex (PSPC) isolated from the culture filtrates of 
the edible mushroom, Tricholoma lobayense, by ethanol precipita-
tion. PSPC contained 40% polysaccharide which consisted of galac-
tose, glucose, mannose, fucose, arabinose and rhamnose, and 
30.05% protein which was composed of 15 amino acids including 
aspartic, glutamic and other acidic amino acids. This glycoprotein 
could restore and increase phagocytic function of macrophages of 
the tumor-bering mice [48,67]. Another example is ATOM from 
Agaricus blazei. It has been suggested that the tumor growth inhibi-
tory effect of ATOM is apparently due to immunological host-
mediated mechanisms so that it is caused by increasing the number 
of peritoneal macrophages, the phagocytosis of polystyrene latex 
beads and the proportion of the third component of complement 
(C3)-positive fluorescent cells in the tumor-bearing mice [48]. A 
liquid medium filtrate separated from the mycelium after sub-
merged cultivation of A. blazei contained mannan-protein complex 
(AB-FP) with a molecular weight of 105–107 Da and a small 
amount of glucose, galactose, and ribose. The yield of AB-FP was 
575 mg/l liquid medium filtrate, and it was described as possessing 
significant antitumor activity after animal studies and in clinical 
experience [8,66]. 
 Glycopeptides are a group structurally similar to glycoproteins 
but with a smaller chain of amino acids. PSP and PSK are examples 
of this class of compounds with antitumor properties. Both products 
are obtained from the extraction of Trametes versicolor mycelia. 
PSK and PSP are Japanese and Chinese products, respectively. 
Both products have similar physiological activities but are structur-
ally different. PSK and PSP are produced from CM-101 and Cov-1 
strains of T. versicolor, respectively. Both products are obtained by 
batch fermentation. PSK fermentation lasts up to 10 days, whereas 
PSP production involves a 64h culture. PSK is recovered from hot 
water extracts of the biomass by salting out with ammonium sul-
fate, whereas PSP is recovered by alcoholic precipitation from the 
hot water extract [31]. PSK is 1,3 and 1,6-monoglucosyl branched 
1,4--D-glucan binding to aspartic, glutamic and other acidic amino 
acids. PSP resembles the PSK structure but is richer in glutamic and 
aspartic acids [48]. The presence of fucose in PSK and of rhamnose 
and arabinose in PSP distinguishes the compounds [19]. There have 
been several decades of successful clinical trials using PSK to treat 
head and neck, upper gastro-intestinal, colorectal, and lung cancers 
with some reported success in treating breast cancer as well [68]. 
While PSK has been almost exclusively developed and tested in 
Japan, PSP, in contrast, is a product of China and continues to be 
assessed for efficacy safety by their scientists and oncologists. 
Many Phase III clinical trials of PSP combined with conventional 
therapies have demonstrated significant benefits against cancers of 
the stomach and lung [12]. Both compounds are of great interest as 
adjuvants of cancer chemotherapy and radiotherapy. They improve 
regular therapeutic efficacy and tolerance (reduction of side ef-
fects), slow down tumor growth and tend to prevent metastasis. On 
a general point of view, global patient health status is significantly 
improved in gastric, intestinal and lung cancer. The precise molecu-
lar mechanism of action of PSP and PSK is still not elucidated. 
Nonetheless, these compounds most likely act through the en-
hancement of the immune system (increasing the number of im-
mune cells and facilitated CDs and cytotoxic T-cell infiltration of 
tumors) more than via direct cytotoxic effects [13,31,48]. KS-2 
from L. edodes is another example of the peptide–polysaccharide 
complex with antitumor properties [60].  
 Proteoglycans are another class of glycoproteins but heavily 
glycosylated. They consist of a core protein with one or more 
coavalently attached glycosaminoglycan chain(s) [48]. An example 
is GLIS from Ganoderma lucidum and PL from Phellinus linteus.
GLIS contains carbohydrates and protein in a ratio of 11.5:1 so that 
the carbohydrate portion is formed by seven different monosaccha-
rides, predominantly D-glucose, D-galactose, and D-mannose in the 
molar ratio of 3:1:1. It is a B-cell stimulating factor [48]. The acidic 
proteoglycan (PL) was shown to be a (1,6) branched type (1,3) 
glycan containing a mixture of monosaccharide including mannose, 
glucose, arabinose and xylose with both - and -link-ages, and a 
variety of amino acids including aspartic acid, glutamic acid, 
alanine, glycine and serine [69]. PL can modulate circulating cyto-
kine responses in lippolysaccharide (LPS)-treated mice and the in 
vivo administration of this compound decreased IL-2 and TNF-
production in splenocytes and enhanced cell apoptosis in macro-
phages and lymphocytes stimulated with LPS in vitro. The inhibi-
tory effect of PL on the growth of MCA-120 tumor cells was asso-
ciated with its immunoregulating properties including the induction 
of IL-12 and interferon (IFN)- production, leading to a TH1 domi-
nant state [48]. LEM is a mycelial extract preparation of L. edodes
harvested before the cap and stem grow, which also revealed anti-
tumor potential [19]. It is a heteroglycan–protein conjugate contain-
ing 24.6% protein and 44% sugars, comprising mostly pentoses as 
well as glucose and smaller amounts of galactose, mannose and 
fructose. It also contains nucleic acid derivatives, B complex vita-
mins, ergosterol, eritadenine (an anticholesteremic amino acid) and 
water-soluble lignins [60]. 
 Besides polysaccharides, several proteins identified in mush-
rooms have been described as having antitumor activity, including 
flammulin from Flammulina velutipes, protein LZ8 from Gano-
derma lucidum, clitocypin from Clitocybe nebularis, and lectins 
from different species (Table 3). The antitumor protein Flammulin 
comprises large amounts of aspartic acid, a higher number of argin-
ine residues than of lysine residues, and no methionine [70]. LZ-8, 
a fungal immunomodulatory protein, is a potent T-cell activator, 
mediating its effects via cytokine regulation of integrin expression 
[48]. It has a sequence of 110 amino acid residues which is blocked 
at the N-terminus by N-acetylation and has less than 2% carbohy-
drate [71]. Clitocypin is a novel cysteine proteinase inhibitor and is 
the first to be characterized from higher fungi. Its sequence of 150 
amino acid residues, M = 16.9 kDa, contains no cysteine or me-
thionine [72,73]. Lectins are storage proteins exhibiting a diversity 
of chemical characteristics. Some of them are monomeric, whereas 
others are dimeric, trimeric or tetrameric. Their molecular weights 
range from 12 to 190 KDa, with sugar contents from 0 to 18%. 
Carbohydrate specificities involve mainly galactose, lactose and N-
acetylgalactosamine. A small number of mushroom lectins are spe-
cific for fucose, raffinose, N-glycolyneuraminic acid and N-acetyl-
D-lactosamine. Several lectins have been described as having po-
tential antitumor/cytotoxic activities, particularly against the human 
colon cancer cell lines HT29 and Caco-2 and breast cancer cell line 
MCF-7 (lectins from Agaricus bisporus), HeLa cells (lectins from 
Grifola frondosa), mouse mastocytoma P815 cells (lectins from 
Tricholoma mongolicum) and sarcoma S-180 cells (lectins from 
Volvariella volvacea). Additionally, lectins from Boletus satanas 
induced the release of tumor necrosis factor- from mononuclear 
cell cultures [71].  
CONCLUDING REMARKS 
 It is estimated that 50% of the annual 5 million metric tons of 
cultivated mushrooms might contain functional or medicinal prop-
erties, which may be used as a source of biologically and physio-
logically active substances [32]. Therefore, it is very important the 
isolation, structural characterization and classification of com-
pounds from mushrooms with potential antitumoral properties. 
Higher fungi may provide potent compounds with potential to be 
used in the prevention and treatment of cancer. However, most of 
the research here reviewed is relatively recent and has been based 
on tumor cell line or animal models. Only little work has been per-
formed at the level of clinical trials in patients. Therefore, despite 
the promising published data, more work needs to be carried out to 
clarify the real use of mushrooms, or their isolated compounds, in 
the prevention and treatment of cancer. 
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